Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PRAECIS PHARMACEUTICALS INC (PRCS)
|
Add to portfolio |
|
|
|
| Price: |
$2.00
| | Metrics |
| OS: |
10.7
|
M
| |
-97
|
% ROE
|
| Market cap: |
$21.4
|
M
| |
|
|
|
Net cash:
|
$40.4
|
M
| |
$3.77
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($29.0)
|
M
| |
|
|
|
EBIT
|
($30.6)
|
M
| |
|
|
| EPS |
($1,425.29)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| Revenues | 7.6 | 3.0 | 0.0 | 1.0 | 59.4 | 85.9 |
| Revenue growth | 154.5% | | -100.0% | -98.3% | -30.8% | |
| Cost of goods sold | 4.0 | 1.7 | 0.0 | 0.0 | 59.4 | 85.9 |
| Gross profit | 3.6 | 1.3 | 0.0 | 1.0 | 0.0 | 0.0 |
| Gross margin | 47.1% | 43.0% | | 100.0% | 0.0% | 0.0% |
| Sales and marketing | 6.0 | 18.9 | 5.6 | 1.8 | 8.7 | 6.4 |
| Research and development | 24.5 | 31.5 | 41.8 | 56.4 | | |
| General and administrative | 7.0 | 8.7 | 9.7 | 9.7 | 7.0 | 5.3 |
| EBIT | -32.5 | -57.7 | -57.1 | -66.9 | -65.2 | -36.5 |
| EBIT margin | -427.2% | -1931.2% | | -6498.3% | -109.7% | -42.4% |
| Pre-tax income | -61.2 | -57.6 | -55.8 | -46.1 | -54.6 | -28.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -61.2 | -57.6 | -55.8 | -46.1 | -54.6 | -28.7 |
| Net margin | -804.7% | -1927.6% | | -4477.6% | -91.9% | -33.4% |
| |
| Diluted EPS | ($5.83) | ($5.51) | ($5.38) | ($0.89) | ($1.10) | ($740.73) |
| Shares outstanding (diluted) | 10.5 | 10.5 | 10.4 | 51.7 | 49.8 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|